Comment

Draft template for assessment report for the development of European herbal monographs and European Union list entries - Revision 6

Retrieved on: 
Thursday, April 18, 2024

The completed comments form should be sent to

Key Points: 
    • The completed comments form should be sent to
      [email protected]
      10
      11
      Keywords

      Committee on Herbal Medicinal Products; HMPC; European Union herbal
      monographs; European Union list of herbal substances, preparations and
      combinations thereof for use in traditional herbal medicinal products; herbal
      medicinal products; traditional herbal medicinal products; traditional use;
      well-established medicinal use; benefit-risk assessment; assessment report

      12

      1
      2

      Changes introduced in section 6 Overall conclusions.

    • Peer-reviewer

      If not the same peer-reviewer
      since last version, all peerreviewers should be listed, and
      the version specified in
      brackets.

    • 22

      23


      on
      .

    • It is a working

      24

      document, not yet edited, and shall be further developed after the release for consultation of the

      25


      .

    • The principle of the template is to make clear
      distinctions between presentation of data (methodology and results)
      and the assessment of the data (?assessor?s comment?).
    • likely from an article but it seems it is concluded by
      the rapporteur; ?According to the author? to be added.
    • Chapters with
      a heading including the word ?conclusion? should include a summary
      of all critical assessment of the assessor for that particular
      chapter.
    • If an assessor?s comment is not needed, the Rapporteur
      should delete the box inserted in the template.
    • ?
      The report should be sufficiently detailed to allow for secondary
      assessment of the available data by other HMPC experts.
    • Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
      preparation(s) and relevant constituents thereof ........................................................... 16

      97
      98

      3.3.

    • Overall conclusions on clinical pharmacology and efficacy ........................................ 27

      Assessment report on
      EMA/HMPC/418902/2005

      Page 4/41

      119

      5.

    • This sections is related to
      available quality standards and there is no need to repeat information
      on all preparations included in the monograph.
    • Search and assessment methodology

      161

      The Rapporteur shall undertake a comprehensive search of relevant
      scientific literature and articles, Acts of law and regulations and
      other relevant sources.

    • Cross-reference to the list of
      references in Annex, which should list separately the references
      supporting the assessment report.
    • 143
      144
      145

      150
      151
      152
      153
      154

      162
      163
      164
      165
      166
      167
      168
      169
      170
      171
      172
      173
      174
      175

      Herbal substance(s)

      Herbal preparation(s)

      Relevant constituents for this assessment report

      Examples of scientific databases to be searched are Medline, PubMed,
      Cochrane Database of Systematic Reviews, EMBASE etc.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 6/41

      176
      177
      178
      179
      180
      181
      182
      183
      184
      185
      186
      187
      188
      189
      190
      191
      192

      Additional relevant references could also be retrieved from the checked
      references.

    • Examples of books are Hagers Handbuch, The Complete German
      Commission E Monographs, PDR for herbal medicines etc.
    • In addition, information from non-EU regulatory
      authorities for examples Health Canada monographs or WHO monographs
      could be searched, if relevant to herbal substances and preparations in
      EU.
    • 221

      225
      226
      227

      232

      When the assessment report is revised, the rapporteur should briefly
      summarise the main changes under this section.

    • Data are collected using the template entitled ?Document
      for information exchange for the preparation of the assessment report
      for the development of European Union monographs and for inclusion of
      herbal substance(s), preparation(s) or combinations thereof in the
      list? (EMEA/HMPC/137093/2006).
    • Assessment report on
      EMA/HMPC/418902/2005

      Page 8/41

      Herbal substance/

      Indication

      Posology and
      method of

      preparation

      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use
      As reported in
      the market
      overview

      As reported in
      the market
      overview

      As reported in
      the market
      overview.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 10/41

      Herbal substance/

      Indication/Medicinal

      Posology and

      preparation

      use

      method of
      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use

      Regulatory Status

      Type of
      regulatory
      status where
      possible, date,
      Country

      287

      This overview is not exhaustive.

    • Clinical Safety/Pharmacovigilance

      836
      837
      838
      839
      840
      841

      See ?Assessment of clinical safety and efficacy in the preparation of
      EU herbal monographs for well-established and traditional herbal
      medicinal products?(EMA/HMPC/104613/2005) for further details.

    • Overall conclusions on clinical safety

      1067

      1068

      In terms of structure, the conclusion should follow the presentation of
      the results above.

    • Overall conclusions

      1092

      1093

      1101

      Describe key aspects only briefly, these will already have been
      described in detail in the respective sections.

    • This section should
      cover all recommended ?well-established use? and ?traditional use?
      indications and conclusions shall be provided for each therapeutic
      indication and each herbal preparation.
    • 1102

      Well established use monograph

      1103
      1104

      The clinical studies supporting well-established use should be
      specified for each therapeutic indication and each herbal preparation.

    • The choice for the wording of traditional use indications vis-?vis existing wordings in monographs in the same therapeutic area should
      be briefly discussed/justified.
    • 1153

      List entry

      1154

      The conclusions should include a statement pointing to the
      possibility/non-possibility to support a European Union list entry.

Christine Lagarde, Luis de Guindos: Monetary policy statement (with Q&A)

Retrieved on: 
Thursday, April 18, 2024

Stock market development and familiarity (language and distance) are considered key determinants for home bias.

Key Points: 
  • Stock market development and familiarity (language and distance) are considered key determinants for home bias.
  • The literature neglects however that investors often invest in foreign funds domiciled in financial centers.

FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments

Retrieved on: 
Thursday, April 18, 2024

FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments

Key Points: 
  • FPF Submits Comments to the Office of Management and Budget on AI and Privacy Impact Assessments
    On April 1, 2024, the Future of Privacy Forum filed comments to the Office of Management and Budget (OMB) in response to the agency’s Request for Information on how privacy impact assessments (PIAs) may mitigate privacy risks exacerbated by AI and other advances in technology.
  • As privacy impact assessments are a well-established means for both public and private entities to assess privacy risks in their services, products, and programs, there is a tremendous opportunity for federal agencies to apply learnings from existing data privacy to the challenges that AI presents as a rapidly evolving technology.
  • Ensuring that the scope and substance of a PIA for AI tools account for role-specific responsibilities and capabilities in the AI system lifecycle.
  • “Whether conducted by the public sector, private companies, or other entities, privacy impact assessments can play an important role in evaluating and mitigating certain risks associated with technology.

How “location, location, location” can lead to “enforcement, enforcement, enforcement”

Retrieved on: 
Friday, April 12, 2024

How “location, location, location” can lead to “enforcement, enforcement, enforcement”

Key Points: 

How “location, location, location” can lead to “enforcement, enforcement, enforcement”

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Equity LifeStyle Properties, Inc. Investors to Inquire About Securities Class Action Investigation – ELS

Retrieved on: 
Saturday, April 6, 2024

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22421 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Media Advisory: Budget 2024 Must Invest in Affordability, Reject Austerity

Retrieved on: 
Thursday, April 4, 2024

OTTAWA, April 04, 2024 (GLOBE NEWSWIRE) -- Bea Bruske, President of the Canadian Labour Congress, is available for comment on what workers are looking for in the upcoming federal budget.

Key Points: 
  • OTTAWA, April 04, 2024 (GLOBE NEWSWIRE) -- Bea Bruske, President of the Canadian Labour Congress, is available for comment on what workers are looking for in the upcoming federal budget.
  • The upcoming budget is an opportunity to deliver much-needed help and address these inequities,” explained Bruske.
  • “We must invest in non-profit rental and social housing, to make homes affordable for every family.
  • “Budget 2024 is an opportunity to fight back against a vision of Canada where wealthy corporations get more tax giveaways, and deeper government spending cuts mean even less help for people who need it most.”

Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG

Retrieved on: 
Wednesday, April 3, 2024

KARL STORZ has communicated that the proposed purchase price represents its “best and final” offer to the Company.

Key Points: 
  • KARL STORZ has communicated that the proposed purchase price represents its “best and final” offer to the Company.
  • During the exclusivity period, KARL STORZ will be conducting diligence and the parties will be negotiating a definitive merger agreement.
  • In conjunction with the letter of intent, Asensus has entered into a fully secured Promissory Note (the “Bridge Loan”) with KARL STORZ.
  • Asensus and KARL STORZ plan to work diligently during the exclusivity period to negotiate and finalize a definitive merger agreement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Equity LifeStyle Properties, Inc. Investors to Inquire About Securities Class Action Investigation – ELS

Retrieved on: 
Wednesday, April 3, 2024

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22421 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22421 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Kona Coin Launches Airdrop for Its Solana-based Meme Token

Retrieved on: 
Wednesday, April 3, 2024

With a meticulously crafted roadmap and a well-defined mission, Kona Coin aspires to emerge as a premier meme cryptocurrency on the Solana blockchain.

Key Points: 
  • With a meticulously crafted roadmap and a well-defined mission, Kona Coin aspires to emerge as a premier meme cryptocurrency on the Solana blockchain.
  • Through its commitment to development, strategic partnerships, and active community engagement, Kona Coin transcends the typical expectations of a meme token.
  • Via its social media platforms, Kona Coin has unveiled an extensive airdrop campaign, offering 80 billion tokens.
  • Moreover, individuals must follow Kona Coin on X (Twitter), retweet the airdrop's pinned post utilizing a specified hashtag, and comment on it.

Sunshine Minting, Inc. Adds Key Industry Expert to Management Team, Dr. Michael H. Gradwell

Retrieved on: 
Tuesday, April 2, 2024

Dr. Gradwell brings extensive experience in manufacturing and quality systems including possessing a Ph.D. in Physical Polymer chemistry and an MBA in Marketing and Leadership.

Key Points: 
  • Dr. Gradwell brings extensive experience in manufacturing and quality systems including possessing a Ph.D. in Physical Polymer chemistry and an MBA in Marketing and Leadership.
  • Tom Power, CEO of Sunshine Minting, Inc., had the following comment regarding Dr. Gradwell, “The addition of Dr. Gradwell brings a new level of technical depth and manufacturing expertise to our leadership team.
  • Mike possesses a deep understanding of manufacturing and quality systems, which will be the key to our continued growth as a company.
  • I am looking forward to welcoming Dr. Gradwell to our Team and introducing him to our Customers!”